Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry

SPP Gampenrieder; Gabriel Rinnerthaler; A Petzer; C Tinchon; D Fuchs; M Balic; S Heibl; H Rumpold; D Egle; AF Zabernigg; CF Singer; J Andel; M Hubalek; M Knauer; Richard Greil

Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry

SPP Gampenrieder, Gabriel Rinnerthaler, A Petzer, C Tinchon, D Fuchs, M Balic, S Heibl, H Rumpold, D Egle, AF Zabernigg, CF Singer, J Andel, M Hubalek, M Knauer, Richard Greil

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

Original language	English
Pages (from-to)	126-+
Journal	ANNALS OF ONCOLOGY
Volume	30
Publication status	Published - 2019
Event	44th Congress of the European-Society-for-Medical-Oncology (ESMO) - Barcelona, SPAIN Duration: 27 Sept 2019 → 1 Oct 2019

Cite this

Gampenrieder, SPP., Rinnerthaler, G., Petzer, A., Tinchon, C., Fuchs, D., Balic, M., Heibl, S., Rumpold, H., Egle, D., Zabernigg, AF., Singer, CF., Andel, J., Hubalek, M., Knauer, M., & Greil, R. (2019). Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry. ANNALS OF ONCOLOGY , 30, 126-+.

Gampenrieder, SPP ; Rinnerthaler, Gabriel ; Petzer, A et al. / Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry. In: ANNALS OF ONCOLOGY 2019 ; Vol. 30. pp. 126-+.

@article{f45ba2d3c5d94373a4c31cec63f501b0,

title = "Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry",

author = "SPP Gampenrieder and Gabriel Rinnerthaler and A Petzer and C Tinchon and D Fuchs and M Balic and S Heibl and H Rumpold and D Egle and AF Zabernigg and CF Singer and J Andel and M Hubalek and M Knauer and Richard Greil",

year = "2019",

language = "English",

volume = "30",

pages = "126--+",

journal = "ANNALS OF ONCOLOGY ",

issn = "0923-7534",

publisher = "Elsevier ",

note = "44th Congress of the European-Society-for-Medical-Oncology (ESMO) ; Conference date: 27-09-2019 Through 01-10-2019",

}

Gampenrieder, SPP, Rinnerthaler, G, Petzer, A, Tinchon, C, Fuchs, D, Balic, M, Heibl, S, Rumpold, H, Egle, D, Zabernigg, AF, Singer, CF, Andel, J, Hubalek, M, Knauer, M & Greil, R 2019, 'Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry', ANNALS OF ONCOLOGY , vol. 30, pp. 126-+.

Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry. / Gampenrieder, SPP; Rinnerthaler, Gabriel; Petzer, A et al.
In: ANNALS OF ONCOLOGY , Vol. 30, 2019, p. 126-+.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry

AU - Gampenrieder, SPP

AU - Rinnerthaler, Gabriel

AU - Petzer, A

AU - Tinchon, C

AU - Fuchs, D

AU - Balic, M

AU - Heibl, S

AU - Rumpold, H

AU - Egle, D

AU - Zabernigg, AF

AU - Singer, CF

AU - Andel, J

AU - Hubalek, M

AU - Knauer, M

AU - Greil, Richard

PY - 2019

Y1 - 2019

M3 - Abstract (Journal)

SN - 0923-7534

VL - 30

SP - 126-+

JO - ANNALS OF ONCOLOGY

JF - ANNALS OF ONCOLOGY

T2 - 44th Congress of the European-Society-for-Medical-Oncology (ESMO)

Y2 - 27 September 2019 through 1 October 2019

ER -

Gampenrieder SPP, Rinnerthaler G, Petzer A, Tinchon C, Fuchs D, Balic M et al. Impact of pertuzumab and T-DM1 on prognosis of HER2-positive metastatic breast cancer (MBC) and factors affecting their efficacy: Results from the AGMT_MBC-registry. ANNALS OF ONCOLOGY . 2019;30:126-+.